Just saw that Todd Bazemore got the full promotion at KALA BIO - moved from interim CEO to permanent President and CEO plus board seat. Dude's been in the biotech game for like 30+ years, so they clearly weren't taking any chances with this one.

What's interesting about Todd Bazemore is his track record jumping between these companies. He was at Dyax before it got acquired by Shire, then moved to Santhera handling US operations, and before all that spent over a decade at Sunovion where he apparently launched 7 new products. That's a pretty solid resume for someone stepping into the top role.

He's been running things as interim CEO since February 2025 anyway, so this feels more like making official what was already happening. For a biotech company dealing with orphan diseases, having someone with that kind of rare disease and commercial experience actually matters. Curious to see what Todd Bazemore does with the role now that he's got the permanent title.